Today: 29 April 2026
Browse Category

NYSE:HIMS 3 July 2025 - 4 December 2025

Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers shares jumped about 8% Thursday to $40.19 after announcing a Canada launch, backed by its Livewell acquisition. The company also agreed to buy YourBio Health and recently launched a diagnostics platform with Quest Diagnostics. Market cap stands near $12.8 billion. Short interest remains high, with 67.6 million shares sold short, or about 36% of the float.
4 December 2025
···
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

HIMS Stock Today (November 18, 2025): Buyback, GLP‑1 Price War and What It Means for Hims & Hers Investors

Hims & Hers shares closed Monday at $35.58, down 3.79%, and traded around $35.00 pre-market Tuesday after announcing a new $250 million share repurchase program. The company faces pressure from a recent sell-off and rising competition in the weight-loss drug market. Shares remain up about 70% over the past year but have dropped 29% in the last month.
18 November 2025
·
Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update

Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update

Hims & Hers Health shares fell about 7–8% to $36.05 Friday after launching its new Labs diagnostic platform with Quest Diagnostics. The company’s market cap stands near $8.2 billion. Labs offers nationwide blood testing and health monitoring through annual subscriptions. The stock remains up roughly 43% year-to-date but trades well below its 52-week high.
14 November 2025
··
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir shares rose after Q3 results beat estimates and the company raised its outlook for a third straight quarter, citing surging AI platform demand. Hims & Hers stock jumped 7% post-market as it entered talks to offer Novo Nordisk’s Wegovy, despite mixed earnings. Sarepta plunged over 20% after a key Duchenne drug trial failed its main goal. Sanmina soared 18% on a strong earnings beat and guidance far above Wall Street forecasts.
4 November 2025
·······
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 November 2025
···
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Hims & Hers Health launched a menopause and perimenopause care program on its Hers platform Oct. 15, triggering a one-day stock surge of up to 16%. Shares quickly reversed, falling 11% to around $52–53 by Oct. 17. The company aims for $1 billion annual revenue in women’s health by 2026. Analysts remain divided, citing high valuation and volatile trading despite rapid revenue growth.
17 October 2025
·
Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Hims & Hers shares jumped 16% on Oct. 15 after launching a menopause care program, trading near $62.80 on Oct. 16, up 7% for the day. The stock has more than doubled in 2025, far outpacing rivals like Teladoc. Regulatory scrutiny from the FDA and FTC triggered brief sell-offs in September. Analyst sentiment remains cautious, with most price targets in the high $30s despite recent gains.
16 October 2025
··
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers Stock Soars on New Menopause Care Expansion – What Comes Next?

Hims & Hers shares surged nearly 13% on Oct. 15 after launching a menopause/perimenopause program on its Hers telehealth platform. The stock traded around $61 by mid-day with 29 million shares exchanged. The company now serves 2.4 million subscribers and reported Q2 revenue of $545 million, up 73% year-over-year. Analysts remain cautious, with most rating the stock Hold or Sell.
15 October 2025
·
Digital Health & Telemedicine Industry Update (June–July 2025)

Digital Health & Telemedicine Industry Update (June–July 2025)

DispatchHealth and Medically Home merged in June 2025, creating one of the largest high-acuity hospital-at-home providers under the DispatchHealth name. Novo Nordisk ended its Wegovy deal with Hims & Hers Health in late June over compounded drug concerns, causing Hims & Hers shares to drop 30%. Teladoc Health shifted strategy after acquiring Catapult Health and UpLift earlier in the year.
3 July 2025
····
1 2

Stock Market Today

  • Smart Share Global Withdraws ADS Listing from Nasdaq
    April 29, 2026, 1:50 PM EDT. Smart Share Global Ltd has formally withdrawn its American Depositary Shares (ADS) listing from the Nasdaq Stock Market. The move was confirmed through the filing of Form 25 with the U.S. Securities and Exchange Commission, which notifies the removal of a security from exchange listing and registration. Nasdaq executed the delisting based on regulatory compliance provisions under the Securities Exchange Act of 1934. Smart Share Global, headquartered in Shanghai, China, did not disclose detailed reasons behind the withdrawal. This development marks a significant shift for the Chinese firm's market presence in the United States, raising questions about future listing strategies or market focus.

Latest article

Sagtec Global Stock Jumps After Record 2025 Revenue, but Costs Tell a Harder Story

Sagtec Global Stock Jumps After Record 2025 Revenue, but Costs Tell a Harder Story

29 April 2026
Sagtec Global reported 2025 audited revenue of $19.1 million, up 49%, driven by strong growth in services. Shares surged 38% to $2.35 in U.S. trading after volatile swings. Operating income dropped 9% to $2.1 million and earnings per share fell to $0.09 from $0.16, reflecting higher costs after the Nasdaq IPO. Net cash from operations rose 187% to $4.1 million.
Dow Jones Today: Why the Blue-Chip Index Is Sliding Before Powell, Big Tech and the Oil Shock

Dow Jones Today: Why the Blue-Chip Index Is Sliding Before Powell, Big Tech and the Oil Shock

29 April 2026
The Dow Jones Industrial Average dropped 320 points, or 0.65%, to 48,821.82 Wednesday afternoon, heading for a fifth straight loss as investors awaited the Federal Reserve’s rate decision and major tech earnings. Brent crude surged 7.14% to $119.20 after reports of a possible extended Iran blockade. Boeing and Goldman Sachs weighed on the Dow, while Amazon rose and Microsoft slipped in midday trading.
Go toTop